Ryoncil® FDA Approval And Market Launch Highlighted At Tandem Transplantation Meetings
Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and ...